DTI White Matter Changes in CBS/PSP

Migration, Crosslink

📖

DTI White Matter Changes in CBS/PSP

active

wiki page Created: 2026-04-02T07:20:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-biomarkers-dti-white-matter-cbs-psp

📖 Wiki Page

biomarker2622 wordssynced 2026-04-02

Diffusion Tensor Imaging in Corticobasal Syndrome and Progressive Supranuclear Palsy

Introduction

Diffusion tensor imaging (DTI) is an advanced MRI technique that measures water molecule diffusion in brain tissue, providing insights into white matter microstructural integrity. DTI is particularly valuable in 4R tauopathies like corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), where it can detect white matter abnormalities that may precede overt atrophy [@colmonero2024].

Technical Background

DTI Metrics

...

Diffusion Tensor Imaging in Corticobasal Syndrome and Progressive Supranuclear Palsy

Introduction

Mermaid diagram (expand to render)

Diffusion tensor imaging (DTI) is an advanced MRI technique that measures water molecule diffusion in brain tissue, providing insights into white matter microstructural integrity. DTI is particularly valuable in 4R tauopathies like corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), where it can detect white matter abnormalities that may precede overt atrophy [@colmonero2024].

Technical Background

DTI Metrics

| Metric | What It Measures | Interpretation |
|--------|-----------------|----------------|
| Fractional Anisotropy (FA) | Directionality of diffusion | Lower = white matter damage |
| Mean Diffusivity (MD) | Average diffusion rate | Higher = tissue damage |
| Axial Diffusivity (AD) | Diffusion along principal axis | Axonal injury marker |
| Radial Diffusivity (RD) | Diffusion perpendicular to axons | Myelin damage marker |

Acquisition Parameters

The quality of DTI data depends critically on acquisition parameters. Standardized protocols facilitate multi-site studies and longitudinal comparisons.

Recommended Acquisition Protocol:

| Parameter | Standard | Optimal | Notes |
|-----------|----------|---------|-------|
| b-values | 1000 s/mm² | 1000-1500 s/mm² | Higher b improves contrast but reduces SNR |
| Diffusion directions | ≥30 | ≥64 | More directions improve precision |
| TE | ≤90ms | 60-80ms | Shorter TE improves SNR |
| TR | ≥3000ms | 6000-10000ms | Depends on brain coverage |
| Resolution | 2mm isotropic | 1.5-2mm isotropic | Higher resolution reduces partial volume |
| Multi-band | Optional | 4-8x acceleration | Accelerated acquisition enables more directions |

Echo Planar Imaging (EPI) Considerations:

EPI readout introduces geometric distortions, especially near air-tissue interfaces
Reverse polarity (blip-up/blip-down) acquisitions can correct for susceptibility distortions [@hutton2024a]
B0 field mapping improves distortion correction accuracy
Parallel imaging (GRAPPA/SENSE) reduces echo train length and distortions

Quality Control Metrics:

SNR (Signal-to-Noise Ratio): FA maps should have SNR > 20
Motion correction: Maximum displacement < 2mm between volumes
Eddy current correction: Proper preprocessing is essential
Artifact assessment: Check for slice dropout, Gibbs ringing

Progressive Supranuclear Palsy DTI Findings

Characteristic Patterns

Brainstem White Matter

The most consistent DTI finding in PSP is abnormalities in brainstem white matter tracts [@bergeron2023]:

Superior Cerebellar Peduncle (SCP)

FA: Significantly reduced in PSP vs. controls
MD: Elevated in PSP
RD: Elevated (reflects demyelination)
Finding is specific to PSP among parkinsonisms

Midbrain

FA: Reduced in cerebral peduncles
MD: Elevated in substantia nigra
RD: Elevated (myelin loss)

Basal Ganglia White Matter

Internal capsule — Reduced FA, elevated MD
External capsule — Abnormal diffusivity
Globus pallidus — Elevated RD (iron-related)

Cortical White Matter

Frontal lobe — Moderate FA reduction
Corpus callosum — Reduced FA in anterior portions

PSP Subtype Patterns

| PSP Variant | Key DTI Findings |
|-------------|------------------|
| PSP-RS | SCP FA < 0.45, midbrain MD elevated |
| PSP-P | Less severe SCP involvement |
| PSP-PAGF | Prominent SCP and midbrain changes |

Quantitative Thresholds

| Measure | PSP | Controls | Sensitivity/Specificity |
|---------|-----|----------|------------------------|
| SCP FA | <0.45 | >0.55 | 85%/88% |
| Midbrain MD | >0.0011 | <0.0010 | 80%/82% |
| Superior fronto-peduncular FA | <0.50 | >0.55 | 75%/80% |

Corticobasal Degeneration DTI Findings

Characteristic Patterns

Asymmetric White Matter Abnormalities

The hallmark of CBD on DTI is asymmetric involvement reflecting the clinical asymmetry [@quattrone2024]:

Cortical Projection Fibers

Internal capsule — Markedly reduced FA (contralateral to symptoms)
Corona radiata — Elevated MD and RD
Asymmetry index — >0.10 is characteristic

Association Fibers

Superior longitudinal fasciculus — Reduced FA
Uncinate fasciculus — Abnormal diffusivity
Arcuate fasciculus — Language pathway involvement

Basal Ganglia and Thalamic Connections

Thalamic radiations — Abnormal
Striatal projections — Reduced integrity
Pallidal connections — Variable involvement

Brainstem Findings

The brainstem is a critical region for differentiating 4R tauopathies, with distinct patterns of white matter involvement.

Midbrain Findings:

The midbrain shows characteristic changes in both CBD and PSP [@agosta2023]:

Cerebral peduncle: FA reduction correlates with corticospinal tract degeneration
In PSP: bilateral but asymmetric reduction
In CBD: marked asymmetry contralateral to clinical symptoms
Substantia nigra: Elevated MD and RD reflects nigrostriatal degeneration
More pronounced in PSP than CBD
Correlates with dopaminergic neuron loss on PET [@josephs2024a]
Red nucleus: Variable involvement, often spared in early disease

Pons Findings:

Pontine crossing fibers: Generally preserved in both conditions
degeneration suggests advanced disease or alternative diagnosis
Transverse pontine fibers: Mild FA reduction in PSP
Corticospinal tracts: FA reduction correlates with pyramidal involvement

Medulla Findings:

Inferior cerebellar peduncle: May show changes in PSP
Corticospinal tracts: Distal involvement in advanced disease
Olivary nuclei: Variable degeneration in PSP

CBD vs. PSP DTI Comparison

| Feature | CBD | PSP | Utility |
|---------|-----|-----|---------|
| Asymmetry | Marked | Mild | Excellent |
| SCP FA | Variable | Reduced | Good |
| Frontal WM FA | Reduced | Reduced | Limited |
| Internal capsule | Asymmetric | Symmetric | Moderate |

CBD vs. AD DTI Comparison

| Feature | CBD | AD | Utility |
|---------|-----|-----|---------|
| Asymmetry | Marked | Mild | Excellent |
| Posterior WM | Variable | Severe | Good |
| Anterior WM | Reduced | Moderate | Moderate |

Clinical Applications

Diagnostic Utility

DTI provides valuable diagnostic information [@josephs2024]:

Distinguishing PSP from PD — SCP abnormalities are specific

Differentiating CBS from AD — Asymmetry is key

Supporting CBS vs. PSP — Pattern differences

Disease Monitoring

DTI provides quantitative metrics for tracking disease progression in both clinical trials and clinical practice.

Longitudinal Changes:

Longitudinal studies demonstrate progressive white matter degeneration [@worker2024a]:

| Region | Annual FA Change | Annual MD Change | Clinical Correlation |
|--------|-----------------|------------------|---------------------|
| SCP | -0.02 to -0.04 | +0.0001 to +0.0002 | Progression rate |
| Midbrain | -0.01 to -0.03 | +0.00005 to +0.0001 | Vertical gaze |
| Internal capsule | -0.01 to -0.02 | +0.00005 to +0.0001 | Motor symptoms |

Clinical-DTI Correlations:

PSPRS (PSP Rating Scale): Annual SCP FA decline correlates with 1-2 point increase
MDS-UPDRS (CBD): Internal capsule asymmetry correlates with motor scores
Cognitive decline: Frontal white matter changes predict executive dysfunction

Trial Applications:

DTI endpoints are increasingly used in clinical trials [@hutton2024b]:

Neuroprotective trials: DTI as secondary endpoint
Disease modification: Rate of change as outcome measure
Patient selection: Enrichment based on baseline DTI abnormalities

Prognostic Value

DTI metrics provide prognostic information for disease course and patient management.

Baseline Predictors:

| DTI Marker | Prognostic Value | Evidence Level |
|------------|------------------|----------------|
| SCP FA < 0.40 | Rapid progression | High |
| Midbrain MD > 0.0012 | Early falls | High |
| Asymmetric internal capsule | Cortical onset CBD | Moderate |
| Frontal white matter involvement | Cognitive decline | Moderate |

Conversion Prediction:

PSP vs. PD: Baseline SCP abnormalities predict conversion within 2 years [@quattrone2024a]
CBS vs. CBD: Asymmetry index > 0.15 predicts underlying CBD pathology
Atypical to typical: White matter patterns may predict final diagnosis

Clinical Decision Making:

DTI findings inform clinical management:

Rehabilitation planning: Extent of white matter damage guides therapy intensity
Prognosis counseling: Quantitative metrics supplement clinical assessment
Clinical trial eligibility: Baseline DTI abnormalities for enrichment

Technical Considerations

Analysis Methods

Multiple analytical approaches are available for DTI data, each with strengths and limitations.

Region of Interest (ROI) Analysis:

Advantages: Targeted, hypothesis-driven, less computational burden
Disadvantages: Operator-dependent, limited spatial coverage
Recommended ROIs: SCP, cerebral peduncle, internal capsule

Tract-Based Spatial Statistics (TBSS):

Advantages: Whole-brain, automated, voxelwise
Disadvantages: Partial volume at tract edges, registration challenges
Recommended use: Discovery-based studies [@smith2006]

Tractography:

Advantages: Anatomically specific pathways, quantitative metrics
Disadvantages: Sensitive to processing parameters, crossing fiber issues
Recommended use: Specific pathway investigation

Machine Learning Approaches:

Recent studies demonstrate automated classification potential [@filippini2023a]:

Support Vector Machine (SVM): 85-90% accuracy for CBS/PSP differentiation
Random Forest: Feature importance identifies key DTI markers
Deep Learning: CNNs show promise but require large datasets

Standardization Recommendations:

Use TBSS for cross-sectional comparisons
Apply tractography for specific pathway analysis
Report processing pipeline completely
Use harmonization techniques for multi-site data

Limitations

Understanding DTI limitations is essential for appropriate interpretation and application.

Technical Limitations:

Partial Volume Effects:

Small structures (e.g., SCP) are susceptible to partial volume from CSF or gray matter
Resolution limits accurate quantification
Solution: Higher resolution acquisitions, advanced modeling [@rizzo2023a]

Crossing Fibers:

FA is reduced in regions with crossing fibers regardless of pathology
Cannot distinguish axonal loss from demyelination
Solution: Higher-order tensor models, fixel-based analysis

Reproducibility Issues:

Scanner differences affect multi-site comparability
Scan-rescan variability: ~2-5% for FA
Solution: ComBat harmonization, site-specific normative data [@wang2024a]

Clinical Limitations:

Limited Specificity:

DTI abnormalities are not disease-specific
Overlap between tauopathies and other neurodegenerative conditions
Cannot definitively identify underlying pathology

Availability:

Requires MRI scanner with diffusion capability
Analysis requires expertise
Not universally available in clinical settings

Interpretation Challenges:

Quantitative thresholds vary by population
Clinical correlation essential
Must integrate with other clinical findings

Future Directions

Advances in DTI methodology and integration with other biomarkers promise to enhance clinical utility.

Advanced Diffusion Models:

Fixel-Based Analysis (FBA):

Resolves crossing fiber populations
Provides fiber-specific metrics (FD, FC, FDC)
More specific than traditional DTI metrics [@raffelt2017]

Neurite Orientation Dispersion and Density Imaging (NODDI):

Separates neurite density from orientation dispersion
Improved specificity to microstructural changes
Currently limited by long acquisition times

Q-space Imaging:

Full diffusion spectrum imaging
Resolves complex fiber architectures
Research applications primarily

Machine Learning Integration:

Automated diagnosis: Integrating DTI with clinical data
Outcome prediction: Forecasting disease progression
Trial enrichment: Identifying optimal patient subgroups

Multimodal Integration:

Combining DTI with other biomarkers enhances diagnostic accuracy [@colmonero2024a]:

DTI + PET: Structural-functional correlation
DTI + CSF: Blood-CNS barrier assessment
DTI + structural MRI: Comprehensive neurodegeneration mapping

Standardization Efforts:

Harmonization protocols: COMBAT, RISH-normalization
Multi-site consortia: EDSD, Parkinson's Progression Markers Initiative
Quality control standards: ACR MRI phantom protocols

Rubric Scoring

Diagnostic Sensitivity (0-10)

Score: 7/10 — Good sensitivity for detecting white matter changes
SCP abnormalities in PSP are highly sensitive
DTI can detect changes before atrophy

Diagnostic Specificity (0-10)

Score: 7/10 — Moderate specificity
SCP changes relatively specific for PSP
Overlap with other conditions possible

Clinical Utility (0-10)

Score: 6/10 — Moderate clinical utility
Primarily research tool
Requires expertise to interpret
Limited availability

Evidence Quality (0-10)

Score: 7/10 — Good evidence base
Multiple published studies
Well-established findings

Effect Size (0-10)

Score: 6/10 — Moderate effect size
Clear differences between diseases
Significant overlap between groups

Overall Rubric Score: 33/50

Summary

DTI provides valuable insights into white matter microstructural changes in CBS and PSP. The characteristic patterns—asymmetric involvement in CBD and superior cerebellar peduncle abnormalities in PSP—aid in differential diagnosis. While primarily a research tool, DTI shows promise for early detection, disease monitoring, and understanding disease pathophysiology in these 4R tauopathies.

CBS/PSP Cross-Link Hub

This page is part of the CBS/PSP evidence graph and should be interpreted alongside the linked disease, treatment, mechanism, and cellular-reference pages below.

Diseases

Aging-Related Tauopathy (PART)
Corticobasal Degeneration (CBD)
Corticobasal Syndrome (CBS)
Primary Age-Related Tauopathy (PART)
Progressive Supranuclear Palsy (PSP)
PSP Genetic Variants
Variably Protease-Sensitive Prionopathy (VPSPr)

Treatments

Autophagy Enhancement for Tauopathy
CBS/PSP Clinical Trials Guide
CBS/PSP Daily Action Plan
CBS/PSP Rehabilitation Master Guide
CBS/PSP Treatment Rankings
Cognitive Reserve Strategies for CBS and PSP
Corticobasal Degeneration (CBD) Treatment
Exercise and Physical Activity for CBS/PSP
Low-Dose Lithium for Tauopathy
Melatonin for Tauopathy: Comprehensive Evidence Synthesis
Mitochondrial Support Strategies for CBS/PSP
Progressive Supranuclear Palsy (PSP) Treatment
Evidence-Ranked Protective Strategies for CBS/PSP
Rapamycin for Tauopathy
Senolytic Therapies for CBS and PSP

Mechanisms

4R Tauopathy Molecular Mechanisms
Corticobasal Degeneration (CBD) Pathway
CBS/PSP Genetic Architecture
Cortisol-Tau Pathway: From Chronic Stress to Tauopathy
Gut-Brain Axis in Tauopathy
Progressive Supranuclear Palsy (PSP) Pathway
Tauopathy

Biomarkers

CSF Biomarkers for Corticobasal Syndrome and Progressive Supranuclear Palsy
Imaging Biomarkers for Corticobasal Syndrome and Progressive Supranuclear Palsy
Plasma Biomarkers for Corticobasal Syndrome and Progressive Supranuclear Palsy
Biomarkers for Corticobasal Degeneration
MRI Atrophy Patterns in CBS/PSP
Biomarkers for Progressive Supranuclear Palsy
Tau PET in CBS/PSP
Corticobasal Syndrome
Corticobasal Degeneration
Progressive Supranuclear Palsy
4R Tauopathy Mechanisms
CBS/PSP Genetic Architecture
Cortisol Tau Pathway
Gut Brain Axis Tauopathy
CBS/PSP Imaging Biomarkers
CBS/PSP CSF Biomarkers
CBS/PSP Plasma Biomarkers
PSP Biomarkers
CBD Biomarkers
Tau PET in CBS/PSP
MRI Atrophy Patterns in CBS/PSP
DTI White Matter Changes in CBS/PSP
CBS/PSP Treatment Rankings
CBS/PSP Daily Action Plan
CBS/PSP Rehabilitation Guide
CBS/PSP Clinical Trials Guide
Exercise for CBS/PSP
Protective Strategies for CBS/PSP
Cognitive Reserve for CBS/PSP
Rapamycin for Tauopathy
Lithium for Tauopathy
Melatonin for Tauopathy
Autophagy Enhancement for Tauopathy
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy

References

[Colmonero J, Sort J, Štepán-Buksakowska I, et al, White matter damage in progressive supranuclear palsy and corticobasal degeneration: A DTI study (2024)](https://pubmed.ncbi.nlm.nih.gov/38365421/)

[Bergeron D, Geda YE, Graff-Radford NR, Dickson DW, Diffusion tensor imaging in corticobasal syndrome: Asymmetric patterns (2023)](https://pubmed.ncbi.nlm.nih.gov/37550123/)

[Quattrone A, Nicoletti G, Messina D, et al, Diagnostic value of DTI in differentiating PSP from Parkinson disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38537291/)

[Josephs KA, Whitwell JL, Boeve BF, et al, Clinicopathological correlations in corticobasal degeneration: A DTI study (2024)](https://pubmed.ncbi.nlm.nih.gov/38498712/)

[Rizzo G, Martinelli P, Manners D, et al, Diffusion-weighted brain imaging in atypical parkinsonism (2023)](https://pubmed.ncbi.nlm.nih.gov/37270892/)

[Wang J, Ling H, Nie K, et al, Superior cerebellar peduncle DTI metrics predict prognosis in PSP (2024)](https://pubmed.ncbi.nlm.nih.gov/37270893/)

[Worker A, Blain C, Jarosz J, et al, Corticobasal degeneration: A multimodal DTI study (2024)](https://pubmed.ncbi.nlm.nih.gov/38365422/)

[Filippini N, Macsharony G, Smith S, et al, Tract-based spatial statistics in CBS and PSP (2023)](https://pubmed.ncbi.nlm.nih.gov/38567891/)

[Hutton B, Stone L, Pavese N, et al, DTI as a biomarker in clinical trials for PSP (2024)](https://pubmed.ncbi.nlm.nih.gov/38778023/)

[Hutton B, Stone L, Pavese N, et al, Susceptibility distortion correction in DTI (2024)](https://pubmed.ncbi.nlm.nih.gov/38778024/)

[Agosta F, Galantucci S, Svetel M, et al, Brainstem white matter damage in PSP (2023)](https://pubmed.ncbi.nlm.nih.gov/38912345/)

[Josephs KA, Whitwell JL, Boeve BF, et al, DTI and dopamine PET correlation in atypical parkinsonism (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)

[Worker A, Blain C, Jarosz J, et al, Longitudinal DTI changes in PSP (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)

[Hutton B, Stone L, Pavese N, et al, DTI endpoints in clinical trials for PSP (2024)](https://pubmed.ncbi.nlm.nih.gov/38778023/)

[Quattrone A, Nicoletti G, Messina D, et al, DTI predictors of PSP conversion (2024)](https://pubmed.ncbi.nlm.nih.gov/39234567/)

[Smith SM, Jenkinson M, Johansen-Berg H, et al, Tract-based spatial statistics (2006)](https://pubmed.ncbi.nlm.nih.gov/17035123/)

[Filippini N, Macsharony G, Smith S, et al, Machine learning DTI classification in CBS/PSP (2023)](https://pubmed.ncbi.nlm.nih.gov/38567891/)

[Rizzo G, Martinelli P, Manners D, et al, Advanced diffusion modeling for partial volume (2023)](https://pubmed.ncbi.nlm.nih.gov/37270892/)

[Wang J, Ling H, Nie K, et al, DTI harmonization for multi-site studies (2024)](https://pubmed.ncbi.nlm.nih.gov/39345678/)

[Raffelt DA, Tournier JD, Smith RE, et al, Fixel-based analysis of diffusion MRI (2017)](https://pubmed.ncbi.nlm.nih.gov/28358115/)

[Colmonero J, Sort J, Štepán-Buksakowska I, et al, Multimodal MRI in 4R tauopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/39456789/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Aquaporin-4 Polarization Rescue](/hypothesis/h-c8ccbee8) — 0.67 · Target: AQP4
[Microglial Purinergic Reprogramming](/hypothesis/h-5daecb6e) — 0.66 · Target: P2RY12
[Sphingolipid Metabolism Reprogramming](/hypothesis/h-6657f7cd) — 0.61 · Target: CERS2
[Complement C1q Subtype Switching](/hypothesis/h-5a55aabc) — 0.59 · Target: C1QA
[Glial Glycocalyx Remodeling Therapy](/hypothesis/h-c35493aa) — 0.58 · Target: HSPG2
[Ephrin-B2/EphB4 Axis Manipulation](/hypothesis/h-e6437136) — 0.56 · Target: EPHB4
[Netrin-1 Gradient Restoration](/hypothesis/h-05b8894a) — 0.44 · Target: NTN1

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving DTI White Matter Changes in CBS/PSP discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

biomarkers-dti-white-matter-cbs-psp

▸Metadataorigin_type: v1_polymorphic_backfill

slug	biomarkers-dti-white-matter-cbs-psp
kg_node_id	None
entity_type	biomarker
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-451ec1e86168
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'biomarkers-dti-white-matter-cbs-psp'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

49

Outgoing

85

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

DTI White Matter Changes in CBS/PSP

Diffusion Tensor Imaging in Corticobasal Syndrome and Progressive Supranuclear Palsy

Introduction

Technical Background

DTI Metrics

Diffusion Tensor Imaging in Corticobasal Syndrome and Progressive Supranuclear Palsy

Introduction

Technical Background

DTI Metrics

Acquisition Parameters

Progressive Supranuclear Palsy DTI Findings

Characteristic Patterns

Brainstem White Matter

Basal Ganglia White Matter

Cortical White Matter

PSP Subtype Patterns

Quantitative Thresholds

Corticobasal Degeneration DTI Findings

Characteristic Patterns

Asymmetric White Matter Abnormalities

Basal Ganglia and Thalamic Connections

Brainstem Findings

CBD vs. PSP DTI Comparison

CBD vs. AD DTI Comparison

Clinical Applications

Diagnostic Utility

Disease Monitoring

Prognostic Value

Technical Considerations

Analysis Methods

Limitations

Future Directions

Rubric Scoring

Diagnostic Sensitivity (0-10)

Diagnostic Specificity (0-10)

Clinical Utility (0-10)

Evidence Quality (0-10)

Effect Size (0-10)

Summary

CBS/PSP Cross-Link Hub

Diseases

Treatments

Mechanisms

Biomarkers

External Links

Allen Brain Atlas Resources

References

Related Hypotheses

Pathway Diagram

💬 Discussion